POC test device for capillary blood samples, 3/13:76
Sarstedt’s Minivette POCT is a device for the precise and hygienic collection, transfer, and subsequent dispensing of small capillary blood samples for point-of-care tests.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
HPLC columns, 3/13:76
Thermo Fisher Scientific’s Syncronis high-performance liquid chromatography columns are now available with 3-mm particle size. The new size complements the existing 1.7- and 5-µm particle sizes.
Horizon Discovery named ‘most promising’ at conference, 3/13:76
Horizon Discovery was named the most promising company at the Personalized Medicine World Conference 2013. Horizon was chosen from 32 shortlisted companies based on technology, historical performance of the company, and forward business plans.
Yellow HRP stain, 3/13:76
Diagnostic BioSystems’ PermaYellow/horseradish peroxidase (HRP) is a substrate-chromogen system designed for immunohistochemistry or in situ hybridization when using horseradish peroxidase. PermaYellow/HRP produces a distinct bright yellow color that can be distinguished easily from other stains.
Liquid-handling extraction products, 3/13:76
Akonni Biosystems has extended its family of smart-tip extraction products for rapidly purifying human genomic deoxyribonucleic acid (gDNA) on Hamilton’s Microlab Star robotic liquid-handling workstations.
Five percent oxalic acid, 3/13:76
Used in conjunction with Alpha-Tec Systems’ NAC-PAC (N-acetylcysteinepackage ) line of digestion/ decontamination, buffering, and resuspension reagents, Alpha-Tec’s five percent oxalic acid is recommended to optimize decontamination conditions of specimens with P. aeruginosa.
Dako, Lilly to collaborate, 3/13:76
Dako, an Agilent Technologies company, has entered into a master framework agreement with Eli Lilly and Company for the development of companion diagnostic tests to identify patients who may be more likely to benefit from an investigational oncology medicine currently under development by Lilly.
Mycology reference guide, 3/13
Mycology Benchtop Reference Guide is an illustrated guide to common fungi. Included are full-color colony and microscopic views. The guide provides a convenient way for students and medical technologists to quickly and confidently identify fungi.
Qiagen adds biomarkers for personalized health care, 3/13:75
Qiagen announced three separate agreements that add biomarkers to its diagnostic pipeline for personalized health care applications to guide treatments with various medicines based on a patient’s genomic information.
PerkinElmer, Verinata to expand access to prenatal test, 3/13:75
PerkinElmer and Verinata Health announced a strategic agreement for expanding access to Verinata’s Verifi test, a comprehensive noninvasive prenatal test (NIPT) for high-risk pregnancies. The Verifi test, performed at Verinata’s CLIA-certified California laboratory, uses a single maternal blood draw at as early as 10 weeks of pregnancy to detect multiple fetal chromosomal aneuploidies. Under terms of the collaboration, PerkinElmer will serve as an exclusive Verinata partner in joint sales and marketing of the Verifi test.